Abstract
Although hypertension, hypercholesterolemia and diabetes mellitus (DM) are recognized as major cardio-metabolic risk factors in primary Acute Coronary Syndrome (ACS) prevention, studies focusing on secondary ACS incidence are scarce. In the present study, the association between the aforementioned factors and 10-year ACS prognosis was evaluated. From October 2003 to September 2004 2,172 consecutive patients with ACS diagnosis, from 6 Greek hospitals, were enrolled. During 2013-14, the 10-year follow-up was performed in 1,918 participants. Baseline clinical factors were assessed through physical examination, medical records and pharmacological management. All-cause mortality and the development of fatal or non-fatal ACS events were recorded through medical records or hospital registries. Logistic regression models were applied to evaluate the impact of baseline clinical status on the ACS prognosis. The 10-year all cause and ACS mortality rate was 32.6 and 17.8%, respectively. Multi-adjusted analysis highlighted that, after taking into account various potential confounders, DM was the sole clinical factor associated with adverse effect on the 10-year ACS fatal incidence [Odds Ratio (OR)=1.35, 95% Confidence Interval (95% CI) 1.01, 1.80, p=0.04]. DM was the only clinical factor that aggravated ACS prognosis, whereas abnormal lipids profile and blood pressure did not seem to determine prognosis. Thus, glycaemic control may play a critical role in the secondary CVD prevention management of ACS patients.
Keywords: Acute Coronary Syndrome, cardiovascular disease, clinical factors, diabetes mellitus, hypercholesterolemia, hypertension, secondary prevention.
Current Vascular Pharmacology
Title:Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Volume: 14 Issue: 3
Author(s): Venetia Notara, Demosthenes B. Panagiotakos, Moscho Michalopoulou, Matina Kouvari, Eleni Tsompanaki, Margarita Verdi, Nikos Vassileiou, Eleni Kalli, Yannis Mantas, Yannis Kogias, Petros Stravopodis, George Papanagnou, Spyros Zombolos, Christos Pitsavos and for the GREECS Study Investigators
Affiliation:
Keywords: Acute Coronary Syndrome, cardiovascular disease, clinical factors, diabetes mellitus, hypercholesterolemia, hypertension, secondary prevention.
Abstract: Although hypertension, hypercholesterolemia and diabetes mellitus (DM) are recognized as major cardio-metabolic risk factors in primary Acute Coronary Syndrome (ACS) prevention, studies focusing on secondary ACS incidence are scarce. In the present study, the association between the aforementioned factors and 10-year ACS prognosis was evaluated. From October 2003 to September 2004 2,172 consecutive patients with ACS diagnosis, from 6 Greek hospitals, were enrolled. During 2013-14, the 10-year follow-up was performed in 1,918 participants. Baseline clinical factors were assessed through physical examination, medical records and pharmacological management. All-cause mortality and the development of fatal or non-fatal ACS events were recorded through medical records or hospital registries. Logistic regression models were applied to evaluate the impact of baseline clinical status on the ACS prognosis. The 10-year all cause and ACS mortality rate was 32.6 and 17.8%, respectively. Multi-adjusted analysis highlighted that, after taking into account various potential confounders, DM was the sole clinical factor associated with adverse effect on the 10-year ACS fatal incidence [Odds Ratio (OR)=1.35, 95% Confidence Interval (95% CI) 1.01, 1.80, p=0.04]. DM was the only clinical factor that aggravated ACS prognosis, whereas abnormal lipids profile and blood pressure did not seem to determine prognosis. Thus, glycaemic control may play a critical role in the secondary CVD prevention management of ACS patients.
Export Options
About this article
Cite this article as:
Notara Venetia, Panagiotakos B. Demosthenes, Michalopoulou Moscho, Kouvari Matina, Tsompanaki Eleni, Verdi Margarita, Vassileiou Nikos, Kalli Eleni, Mantas Yannis, Kogias Yannis, Stravopodis Petros, Papanagnou George, Zombolos Spyros, Pitsavos Christos and for the GREECS Study Investigators , Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study, Current Vascular Pharmacology 2016; 14 (3) . https://dx.doi.org/10.2174/1570161113666150916093451
DOI https://dx.doi.org/10.2174/1570161113666150916093451 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Hypertension in Hemodialysis Patients
Current Hypertension Reviews Prognostic Significance of Asymptomatic Myocardial Ischemia in Women vs. Men
Current Pharmaceutical Design Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Therapies Targeting Oxidative Stress for Human Diseases: Where Are We Now?)
Current Pharmaceutical Biotechnology Preoperative Pulmonary Assessment: A Review
Current Respiratory Medicine Reviews Emerging Anticoagulants
Current Medicinal Chemistry Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Neural Mechanism of Exercise: Neurovascular Responses to Exercise
CNS & Neurological Disorders - Drug Targets Genetic Basis of Renal Mass in Rat Models
Current Hypertension Reviews Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Tartaric Acid Enhances Adrenergic Receptor Activity: Test of a General Theory of Extracellular Aminergic GPCR Enhancer Discovery
Current Drug Discovery Technologies Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design